Date published: 2026-5-7

1-800-457-3801

SCBT Portrait Logo
Seach Input

GW182 Inhibitors

GW182 inhibitors are a class of chemical compounds that primarily target a protein known as GW182. These inhibitors have garnered significant attention in the field of molecular biology and biochemistry due to their role in the regulation of gene expression and cellular processes. GW182 is a crucial component of the RNA-induced silencing complex (RISC), which plays a central role in RNA interference (RNAi) pathways in eukaryotic organisms. In RNAi, small RNA molecules guide RISC to target messenger RNAs (mRNAs) for degradation or translational repression, effectively silencing the expression of specific genes. GW182 inhibitors are designed to interfere with this process by binding to GW182 and disrupting its interactions with other components of the RISC complex, ultimately impairing the RNAi machinery's ability to carry out gene silencing.

The chemical structures and mechanisms of GW182 inhibitors can vary, but their common goal is to impede the function of GW182 in post-transcriptional gene regulation. By doing so, these inhibitors provide valuable tools for researchers studying the intricacies of gene expression and the role of RNAi in cellular processes. Furthermore, their use in laboratory settings allows scientists to explore the consequences of inhibiting GW182, shedding light on its broader functions and implications for basic biological research

SEE ALSO...

Items 1 to 10 of 12 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Actinomycin D

50-76-0sc-200906
sc-200906A
sc-200906B
sc-200906C
sc-200906D
5 mg
25 mg
100 mg
1 g
10 g
$74.00
$243.00
$731.00
$2572.00
$21848.00
53
(3)

Actinomycin D intercalates into DNA and inhibits RNA polymerase, potentially reducing the transcription of the GW182 gene and subsequently decreasing its protein expression.

Fluorouracil

51-21-8sc-29060
sc-29060A
1 g
5 g
$37.00
$152.00
11
(1)

As a pyrimidine analog, 5-Fluorouracil incorporates into RNA, potentially causing aberrant transcription and translation processes that could decrease GW182 protein levels.

Cycloheximide

66-81-9sc-3508B
sc-3508
sc-3508A
100 mg
1 g
5 g
$41.00
$84.00
$275.00
127
(6)

Cycloheximide inhibits protein synthesis in eukaryotic organisms, which could lead to a general decrease in protein levels, including GW182.

Rapamycin

53123-88-9sc-3504
sc-3504A
sc-3504B
1 mg
5 mg
25 mg
$63.00
$158.00
$326.00
233
(4)

Rapamycin inhibits the mTOR pathway, which plays a crucial role in protein synthesis. Inhibition of this pathway could result in reduced GW182 protein expression.

Doxorubicin

23214-92-8sc-280681
sc-280681A
1 mg
5 mg
$176.00
$426.00
43
(3)

Doxorubicin intercalates into DNA and inhibits topoisomerase II, potentially disrupting normal transcription and translation processes and decreasing GW182 protein levels.

Etoposide (VP-16)

33419-42-0sc-3512B
sc-3512
sc-3512A
10 mg
100 mg
500 mg
$51.00
$231.00
$523.00
63
(1)

Etoposide stabilizes the DNA-topoisomerase II complex, causing DNA damage and potentially decreasing the transcription and translation of GW182.

Camptothecin

7689-03-4sc-200871
sc-200871A
sc-200871B
50 mg
250 mg
100 mg
$58.00
$186.00
$94.00
21
(2)

Camptothecin inhibits topoisomerase I, potentially leading to DNA damage and a decrease in GW182 protein expression through disrupted transcription and translation processes.

Methotrexate

59-05-2sc-3507
sc-3507A
100 mg
500 mg
$94.00
$213.00
33
(5)

Methotrexate is a folate analog that inhibits dihydrofolate reductase, potentially leading to decreased nucleotide synthesis and reduced transcription of the GW182 gene.

Chloroquine

54-05-7sc-507304
250 mg
$69.00
2
(0)

Chloroquine raises endosomal pH, potentially affecting cellular processes and mRNA stability, which could result in decreased GW182 protein levels.

Emetine

483-18-1sc-470668
sc-470668A
sc-470668B
sc-470668C
1 mg
10 mg
50 mg
100 mg
$440.00
$900.00
$1400.00
$2502.00
(0)

Emetine inhibits protein synthesis at the level of translation elongation, potentially leading to a decrease in GW182 protein levels.